BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao X, Sun W, Ren Y, Lu Z. Therapeutic potential of p53 reactivation in cervical cancer. Crit Rev Oncol Hematol 2021;157:103182. [PMID: 33276182 DOI: 10.1016/j.critrevonc.2020.103182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Peng Y, Pan J, Ou F, Wang W, Hu H, Chen L, Zeng S, Zeng K, Yu L. Fenbendazole and its synthetic analog interfere with HeLa cells’ proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway. Chemico-Biological Interactions 2022;361:109983. [DOI: 10.1016/j.cbi.2022.109983] [Reference Citation Analysis]
2 Guo Y, Chen J, Zhang X, Fang M, Xu M, Zhang L, Rao E, Xin Y. Recombinant Human Adenovirus-p53 Therapy for the Treatment of Cervical Cancer: A Meta-Analysis. Front Oncol 2021;11:748681. [PMID: 34733786 DOI: 10.3389/fonc.2021.748681] [Reference Citation Analysis]
3 Xiong J, Li G, Mei X, Ding J, Shen H, Zhu D, Wang H. Co-Delivery of p53 Restored and E7 Targeted Nucleic Acids by Poly (Beta-Amino Ester) Complex Nanoparticles for the Treatment of HPV Related Cervical Lesions. Front Pharmacol 2022;13:826771. [DOI: 10.3389/fphar.2022.826771] [Reference Citation Analysis]
4 Chitsike L, Duerksen-Hughes PJ. Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review. Front Oncol 2021;11:730412. [PMID: 34490123 DOI: 10.3389/fonc.2021.730412] [Reference Citation Analysis]